26 - 27 November 2019 | London, UK
Practical strategies for navigating the capricious regulatory landscape and maximising the value of IP within Life Science
Intellectual Property is the life blood of any Life Science organisations, and the effective management, protection, and enforcement of IP’s is essential to achieve success in such a competitive market. Life Science IP is the only IP event designed for in-house IPR professionals with a focus on the key issues of the year, including the Doctrine of Equivalents, Second-Medical use claims and SPCs. Furthermore, the event will also provide attendees with commercial strategies for maximising the value of their existing IP portfolio and will simultaneously explore the viability reduced-costs methods of IP protection.
Early Confirmed Speakers Include
Lord Neuberger
Law Lord
UK House of Lords
Aaron Smethurst
Director, Intellectual Property Policy
UCB
Dr. Matthias Zigann
Presiding Judge
Regional Court Munich I
Kevin Mooney
Chairman of the Rules and Procedure Committee
UPC
Dr. Judy Jarecki-Black
Head, Patent Prosecution and Patent Litigation, Animal Health
Boehringer Ingelheim Animal Health
Jane Lambert QC
Barrister
4-5 Gray's Inn Square
Martyn Fish
Partner
HGF Limited
Michelle Davies
Legal Director
HGF Limited
Professor Mark Engelman QC
Head of Intellectual Property, Barrister
Hardwicke Chambers
Dr Sven Bostyn Lic.Jur., LLM, PhD
Associate Professor of Biomedical Innovation Law
Law Center for Advanced studies in Biomedical Innovation Law
Dr Guido Pontremoli
Corporate IP Patent Director
Chiesi
Harriet Strimpel
Chief IP Counsel
New England Biolabs
Ehab Shakour
CTO & IP Director
InnoSphere
Stephane Hauduc
Discovery Chemistry and Intellectual Property Manager
Destiny Pharma
Susan Dunn
CEO
Harbour Litigation Fund
Rahela Penovski
CEO
Cognedt
Nikolaos Papageorgiadis
Senior Lecturer
University of Liverpool
Denis Bayada
Product Manager Orbit
Questel
Fabienne Persijn
Key Account Executive
Questel
Bin Zheng
Partner, Patent Attorney
Unitalen Attorneys At Law
Sally Bannan
Senior European Patent Attorney
GE
Benefits of attending
20+
SPEAKERS
80+
PARTICIPANTS
75%
PRACTITIONER
ATTENDEES
15+
HOURS
DEDICATED NETWORKING
Key Highlights to be addressed:
Receive updates and insights directly from the lawmakers, including QC Barrister Mark Engelman.
Learn more about the efficacy of patenting anti-bodies, biosimilars and bio-equivalents and how local experts are managing this at a regional level
Receive updates on the implications of recently concluded case law, including the Actavis 'Skinny Labelling' case. Hear how expert law firms and life sciences businesses will be adapting their IP strategy accordingly.
Work with industry experts, specialist law firms, licensing businesses and in-house counsels to generate effective IP portfolio management, commercialisation and monetisation strategies.
Discuss the viability of alternative forms of IP protection, including trade-secrets, confidential information, trademarks and copyright.
What our past attendees had to say about our events
